You are here
P&T June 2014
For patients with low back pain, skeletal muscle relaxants are often initiated after failure of first-line analgesics. However, these medications (reviewed in this article) are controversial alternatives that carry risks of adverse effects and increased cost.
An array of natural substances purported to possess disease-modifying qualities for osteoarthritis are designated as “dietary supplements” and thus avoid rigorous FDA regulation. Substantial scientific evidence for the efficacy of these agents is elusive.
FDA starts light-touch inspections for some imports.
FDA approvals, drug indications, and updates
Apremilast (Otezla) for active psoriatic arthritis, omalizumab (Xolair) for chronic idiopathic urticaria, and grass pollen allergen extract (Oralair) for grass pollen-induced allergic rhinitis with or without conjunctivitis
The American Association for Cancer Research meeting included reports on new agents for breast cancer and melanoma.
The American Psychiatric Association meeting offered updates on treatments for bipolar depression, autism, and depression.